Impact of diabetes on cancer chemotherapy outcome: A retrospective analysis

International Journal of Diabetes in Developing Countries

Volumn 27, Issue 4, 2007, Pages 122-128

  Attili, V ^a   Bapsy, P ^a   Dadhich, Hemant ^a   Batra, Ullas ^a   Lokanatha, D ^a   Babu, K ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Cancer chemotherapy; Diabetes

Indexed keywords

EID: 38949141551     PISSN: 09733930     EISSN: None     Source Type: Journal    
DOI: 10.4103/0973-3930.38631     Document Type: Article

References (24)

1. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005;2:48-53.
2. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding roteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
3. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-betal on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
4. Giovannucd E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003;35:694-704.
5. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003;157:1092-100.
6. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-53.
7. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, et al. Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8.
8. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: Exploring the hyperinsulinemia hypothesis. Br J Cancer 2001;84:417-22.
9. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
10. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5.
11. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21:433-40.
12. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madamas Y, et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
13. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
14. de Vita VT Jr, Hubbard SM, Longo DL. the chemotherapy of lymphomas: Looking back, moving forward-the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1987;47:5810-24.
15. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005;6:103-11.
16. Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003;53:227-44.
17. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003;21:3580-7.
18. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10.
19. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-92.
20. Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: A focus on breast cancer. Med Care 1999;37:601-14.
21. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, et al. Cisplatin, fluorouracil and leucovorin augmented by interferon alfa-2b in head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 1993;11:360-8.
22. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, et al. Cisplatin, fluorouracil and leucovorin augmented by interferon alfa-2b in head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 1993;11:360-8.
23. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004;100:1179-85.
24. Ellis ME, Weiss RB, Korzun AH, Rice MA, Norton L, Perloff M, et al. Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer: A cancer and leukemia group B (CALGB) study. Am J Clin Oncol 1986;9:533-6.